Member Info for opti_mystic

Reading between the lines I'd say the small investment from CC is a very signifcant nod to shareholders that all is well, I'd say exceptionally well, in the AVA6103 trial. CC has 3.6 million options. She really does not need to buy further shares. If Avacta goes for anywhere near what we hope it will go for today's purchase is basically financially iirelevant. So why buy £22,500 worth of shares? You don't need to do that, but it says I'm confident in what I'm seeing and here's a clue about how it's going.

The strategic raise, another that has been over subscribed, says to the market we can raise whatever we need to raise whenever we need to raise it, you don't have to worry about the CLN anymore, we have it covered. The company is a much better place than ot was before RH came on board.

I'm happy with my average 😁. I think we'll have a deal on AVA6000 in the summer just need the data to land at the end of June. I expect that will give the sp a bit of a boost. Possible Nasdaq listing after that. Then more information on the warheads for 6207 in Q3, so that may involve somehow trying not to give away which BP's assets we're using and therefore who the potential partner is, which I see as a bit of a condrum. Maybe they'll just say who knows but naming a big name, and will have to be a big name changes things if that get partnered. Then 6103 data in December. I think there's only a few weeks left to buy at less than £1.

I'm hopeful they will not release anything at all until the information has matured sufficiently to make them sit up and recognise we're worth a fortune. It prevents a speculative low offer early and buys us time to obtain what I expect to be extremely good data by years end. The longer we hear nothing on 6103 the better it is as far as I'm concerned. They'll be getting through the dose escalations by now and if get no bad news in the 4 weeks, I think we're onto a winner. If the median tumour blood ratios in AVA6000 is now 117-1 that data in 6103 must be pretty incredible being as we're expecting a significant improvement on the pre-clinical 99-1.

Yes there is an option to pay the loan off early.

Steadyman, I was there and I'd say they were at great pains not to give anything away that could be construed as price sensitive. I'm afraid it is probably something as prosaic as the sound quality being absolutely shocking which it was on the day. There were microphones for the speakers to speak into but I fear if there was any actual amplification it was tiny, they may as well have just been speaking without it. I saw the tech guys going up throught the presentation although what they were doing I couldn't say, it was a case of PPPPPP and they didn't have PP so they had PPP.

Yes he was talking triple payload for 6207.

In terms of a low ball bid, CC said in answer to the question about will we get data on an on-going basis for AVA6103 like we did for 6k that she's been mulling that over and they hadn't made a decision on that yet. It was then put to her that if BP had such data early before it had matured it might invite an unwelcome low ball bid, to which she replied 'You read my mind'. Being as BP need reliable data in order to make a bid, I think you can take it as read such data that would be sufficient for BP to be enticed into making one will not be available until the end of the year when the data is mature enough for Avacta to want to release it.

At science day I was lucky enough to spend some time with Francis Wilson. I asked him about AVA7100 and essentially it is on the back burner. Part of the reason is the development of AVA6207 being more of a priority with our limited resources and another part is that they were surprised by how well our technology works in low FAP tumours. I also asked him about a triple payload and whilst possible he said it would be very ,very complex.

FWIW I have a sneaky suspicion 6103 may possibly work better in low FAP tumours than in high FAP tumours, I know that's counter intuitive but it's a little theory I have.

I was busy yesterday, but I didn't understand on what basis there was a bond payment as it didn't seem to meet any of the criteria set out by Bella below. My understanding was there would no payments until July 2026 or if one the criteria Bella shows was met. Can someone explain what happened?

Scratch that relates to May 8th not today.

At 08:23 a trade or trades wen t through when the bid/ask was 87/90 but the share was traded at 81p. How does that happen?

Hi LDA, CC said the update will be in two spearate releases because there was too much data to go in one data release.

To be fair Ice, I think 4,900 of those are mine!

Some chunky buys today. There was another one around the same size at about 12:30. Seems there's interest (finally) from non-retail.

The other thing mentioned yesterday that I was interested to hear is that they very much expect the tumour /plasma ratio to improve from the 99:1 noted in the pre-clinical mouse trials. The reason given was that mice have FAP in the blood stream at a much higher level than humans, the difference stated as ten times as much FAP in mice. This would account for the change we saw from pre-clincial to humans in AVA6000 and explains why they are confident of another big improvement when they see the numbers for 6103. Less off target cleavage means improved safety. CC said they would be delighted with 99-1 though. It sounds as if that's really all they need, but obviously if they do get an improvement that makes it even better.

Cj, in six months time things will be very different from how they are now. The whole team oozed confidence yesterday. CC was working the room to meet as many people as possible. A very talented team. I know it's been a long road, but I think you can relax and see what happens between now and the end of the year.

There's another possibility. Maybe with the data we have we're able to obtain some sort of fast track approval possibly even breakthrough therapy, bearing in mind there is literally nothing available that's recommended for SGC. That reduces the time to market and makes the drug more valuable. A deal is then signed for AVA6000 with this designation in hand including some sort of upfront payment. This will fund the company for sometime and enables a listing on the Nasdaq at a much higher price than we're at today in view of the first deal being done and now with much more capital in the bank. This funds us way beyond first readout for 6103.

Understood BV, fair comment. I made a post some time ago about all roads leading to Astra Zeneca, they're the only company who have access to PARPi technology and ATRi technology and have a major threat to their current lead asset. In pretty much everything I looked at Avacta intersected with AZN. It's the perfect fit for both companies. Our USP is drastically reduced toxicity.

BV, companies can usually get permission to use these in patent molecules for research or similar reasons.

These are normally bio-compatible, the risk is typically in premature release of the payload outside the tumour essentially on its way to the tumour.